Trial Profile
Phase II study of hydroxyurea [hydroxycarbamide] in patients with recurrent and/or nonresectable meningioma [brain cancer].
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2021
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Brain cancer; Meningioma
- Focus Therapeutic Use
- 19 Feb 2021 Status changed from active, no longer recruiting to completed.
- 23 Sep 2005 New trial record.